Form 4 for AVTX Avalo Therapeutics, Inc.
Accepted 2026-03-31 00:00:00 ET · period of report 2026-03-28 · accession 0001586785-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-31 | 2026-03-28 | AVTX | NEIL GARRY ARTHUR | CEO, Dir | M - OptEx | — | +64.9K | 112.0K | +138% | — |
| D | 2026-03-31 | 2026-03-28 | AVTX | NEIL GARRY ARTHUR | CEO, Dir | F - Tax | $13.89 | -21.9K | 90.1K | -20% | -$304.1K |
| D | 2026-03-31 | 2026-03-28 | AVTX | NEIL GARRY ARTHUR | CEO, Dir | M - OptEx | $0.00 | -64.9K | 64.9K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-28 | M | A | 64,866 | — | 112,006 | D | — | — | (F1) Restricted stock units convert into common stock on a one-for-one basis. |
| 2 | Common | Common Stock | 2026-03-28 | F | D | 21,892 | $13.89 | 90,114 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2026-03-28 | M | D | 64,866 | $0.00 | 64,867 | D | — · — to — | 64,866 Common Stock | (F1) Restricted stock units convert into common stock on a one-for-one basis. (F2) On August 13, 2024, the Reporting Person was granted 194,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. |